Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

69.87 +0.18 (+0.26%)
Streaming Delayed Price Updated: 12:47 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
66 67 Next >
AstraZeneca Surges To 50-Day Line After Breast Cancer Drug Tops Chemo
The companies are still testing to see if their drug has a benefit on overall survival. 
Via Investor's Business Daily
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:  
Via Benzinga
Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
From AstraZeneca
Via Business Wire
On the Road to Halving Cancer: The 2023 Biotech Advancements Igniting Hope
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 20, 2023 – USA News Group – Earlier this year, the US White House requested over $2.8 billion in funding from Congress... 
Via FinancialNewsMedia
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
One in eight women will be diagnosed with breast cancer during 
Via Benzinga
AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment
From AstraZeneca
Via Business Wire
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients  
Via Benzinga
FASENRA met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
From AstraZeneca
Via Business Wire
Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories
Benzinga Qualcomm Announces Chip Supply Agreement With Apple 
Via Benzinga
What's Going On With AstraZeneca Stock Today?
Shares in European pharmaceutical giant AstraZeneca Plc (NASDAQ: AZN) are down amid speculations swirling around the potential departure of AstraZeneca's Chief Executive, Pascal Soriot. 
Via Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria 
Via Benzinga
TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
From AstraZeneca
Via Business Wire
4 Top-Tier Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Deals can still be found with the Nasdaq Composite roughly 14% below its record-closing high. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Cancer Drug Rybrevant Shows Improvement In Broader Lung Cancer Population
Janssen, a unit of Johnson & Johnson (NYSE: JNJ),  
Via Benzinga
FDA Seeks Further Safeguards for AstraZeneca's Ultomiris Therapy, But Efficacy Not in Question
The FDA has issued a complete response letter (CRL) regarding AstraZeneca Plc's (NASDAQ: 
Via Benzinga
Exposures Product Safety
3 Forever Stocks to Buy With $100
With $100 or less, you can buy at least one share of one of these top stocks. 
Via The Motley Fool
Facebook News To Shut Down In Europe, Warner Bros. Discovery Revises Outlook As Strike Bites, Manchester United No Longer Up For Sale: Today's Top Stories
Benzinga Why Facebook News is Shutting Down in Europe: What It Means for Users? 
Via Benzinga
Legal Twist In Drug Price Negotiation: Federal Judge Quits Case Amid Allegations Of Stock Ownership
On Friday, Judge Thomas Rose, serving in the U.S. 
Via Benzinga
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
The genetic test maker is rapidly increasing test volumes. 
Via The Motley Fool
Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet
The Biden administration's move to lower drug prices has prompted a flurry of legal challenges. 
Via Benzinga
Ambrx Biopharma Has Surged 483% This Year. But It Could Just Be Getting Started.
The company has another update on its prostate cancer program that could further prod shares. 
Via Investor's Business Daily
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: 
Via Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings
Catalent Inc (NYSE: CTLT), valued at around $8 billion, has finalized a deal with activist investor Elliott Investment Management.  
Via Benzinga
Exposures COVID-19
Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government
AstraZeneca Plc (NASDAQ: AZN) announced its legal challenge against the U.S. 
Via Benzinga
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy. 
Via InvestorPlace
AstraZeneca urges re-examination of unintended consequences of Inflation Reduction Act on American cancer and rare disease patients
From AstraZeneca
Via Business Wire
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS